Ribociclib and Letrozole Tablets

FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer. On July 18, 2018, the Food and Drug Administration expanded the indication for ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

The Kisqali Femara Co-Pack is a prescription that contains two medications, ribociclib (Kisqali) and letrozole (Femara), used as a first-line treatment for adults who have advanced or metastatic hormone-receptor-positive human epidermal growth factor-2 receptors (HER2)-negative breast cancer.1 Metastatic cancer is cancer that has spread from the primary site to other areas of the body.

• Generic Name: Ribociclib and letrozole
• Brand Name(s): Kisqali Femara Co-Pack
• Drug Availability: Prescription
• Administration Route: Oral
• Therapeutic Classification: CDK4/6 inhibitor and aromatase inhibitor
• Available Generically: No
• Active Ingredient: Ribociclib and letrozole
• Dosage Form(s): Tablet